Everything below concerns alpha-MSH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
The sulfur dioxide is used for the production of sulfuric acid, which is necessary for the leaching process. If deposits of zinc carbonate, zinc silicate, or zinc-spinel (like the Skorpion Deposit in Namibia) are used for zinc production, the roasting can be omitted. For further processing two basic methods are used: pyrometallurgy or electrowinning. Pyrometallurgy reduces zinc oxide with carbon or carbon monoxide at 950 °C (1,740 °F) into the metal, which is distilled as zinc vapor to separate it from other metals, which are not volatile at those temperatures. The zinc vapor is collected in a condenser. The equations below describe this process:
Upon Allied victory concluding the Second World War (1939–1945), the members of the Grand Alliance resumed their pre-war geopolitical rivalries and ideological tensions which disunity broke their anti-fascist wartime alliance through the concept of totalitarianism into the anti-communist Western Bloc and the Marxist–Leninist Eastern Bloc. The renewed competition for geopolitical hegemony resulted in the bi-polar Cold War (1947–1991), a protracted state of tension (military and diplomatic) between the United States and the Soviet Union which often threatened a Soviet–American nuclear war, but it usually featured proxy wars in the Third World. With the end of the Grand Alliance and the start of the Cold War, anti-fascism became part of both the official ideology and language of communist states, especially in East Germany. Fascist and anti-fascism, with the latter used to mean a general anti-capitalist struggle against the Western world and NATO, became epithets widely used by Marxist–Leninists to smear their opponents, including democratic socialists, libertarian socialists, social democrats and other anti-Stalinist leftists. The events that precipitated the Cold War in Europe were the Soviet and Yugoslav, Bulgarian and Albanian military interventions to the Greek Civil War (1944–1949) on behalf of the Communist Party of Greece; and the Berlin Blockade (1948–1949) by the Soviet Union.
== Role in proteins == Quinoproteins generally embed the cofactor in a unique, six-bladed beta-barrel structure. Some examples also have a heme C prosthetic group and are termed quinohemoproteins. Although quinoproteins are mostly found in bacteria, a Coprinopsis cinerea (fungus) pyranose dehydrogenase has been shown to use PQQ in its crystal structure. PQQ also appears to be essential in some other eukaryotic proteins, albeit not as the direct electron carrier. The mammalian lactate dehydrogenase requires PQQ to run but uses NADH as the direct redox cofactor. PQQ seems to speed up the reaction by catalyzing the oxidation of NADH via redox cycling.
Sources: en.wikipedia.org
== Biosynthesis == Prostaglandin E1 is biosynthesized on an as-needed basis from dihomo-γ-linolenic acid (an omega-6 fatty acid) in healthy humans without coronary artery disease and/or a genetic disorder.
nirantarāndhakārita-digantara-kandaladamanda-sudhārasa-bindu-sāndratara-ghanāghana-vṛnda-sandehakara-syandamāna-makaranda-bindu-bandhuratara-mākanda-taru-kula-talpa-kalpa-mṛdul̥a-sikatā-jāla-jaṭila-mūla-tala-maruvaka-miladalaghu-laghu-laya-kalita-ramaṇīya-pānīya-śālikā-bālikā-karāra-vinda-galantikā-galadelā-lavaṅga-pāṭala-ghanasāra-kastūrikātisaurabha-medura-laghutara-madhura-śītalatara-saliladhārā-nirākariṣṇu-tadīya-vimala-vilocana-mayūkha-rekhāpasārita-pipāsāyāsa-pathika-lokān from the Varadāmbikā Pariṇaya Campū by Tirumalāmbā, composed of 195 Sanskrit letters (428 letters in the roman transliteration, dashes excluded), thus making it the longest word ever to appear in worldwide literature. Each hyphen separates every individual word this word is composed of. The approximate meaning of this word is:
== Early career == De Castro was born in Guarda, on 9 November 1878. He was part of the Constitutional junta that governed Portugal in 1915. He later served as Governor-General of Mozambique between 1915 and 1918. He was a prominent participant in the attempted coup of 11 January 1919 which took place after the assassination of Sidónio Pais.
Sources: en.wikipedia.org
=== Biotechnology === BASF was cooperating with Monsanto Company in research, development and marketing of biotechnology. In correlation to this work, BASF has licensed many gene editing tools including CRISPR Cas9 and CRISPR Cas12a (Cpf1). The BASF Plant Science subsidiary produces the Amflora and Starch Potato genetically modified potato with reduced amylose. In 2010 BASF conducted Department of Environment, Food and Rural Affairs approved trials of genetically modified potatoes in the United Kingdom. Starch Potato was authorised for use in the USA in 2014. Other GM crops are Phytaseed Canola varieties with phytase, sulfonylurea herbicide tolerant soybean and drought tolerant corn (with cold shock protein B) developed with Monsanto.
First, aspartic acid is converted via β-aspartyl semialdehyde into homoserine by two reduction steps of the terminal carboxyl group (homoserine has therefore a γ-hydroxyl, hence the homo- series). The intermediate aspartate semialdehyde is the branching point with the lysine biosynthetic pathway, where it is instead condensed with pyruvate. Homoserine is the branching point with the threonine pathway, where instead it is isomerised after activating the terminal hydroxyl with phosphate (also used for methionine biosynthesis in plants). Homoserine is then activated with a phosphate, succinyl or an acetyl group on the hydroxyl. In plants and possibly in some bacteria, phosphate is used. This step is shared with threonine biosynthesis. In most organisms, an acetyl group is used to activate the homoserine. This can be catalysed in bacteria by an enzyme encoded by metX or metA (not homologues). In enterobacteria and a limited number of other organisms, succinate is used. The enzyme that catalyses the reaction is MetA and the specificity for acetyl-CoA and succinyl-CoA is dictated by a single residue. The physiological basis for the preference of acetyl-CoA or succinyl-CoA is unknown, but such alternative routes are present in some other pathways (e.g. lysine biosynthesis and arginine biosynthesis). The hydroxyl activating group is then replaced with cysteine, methanethiol, or hydrogen sulfide. A replacement reaction is technically a γ-elimination followed by a variant of a Michael addition.
Ubiquitin is the most-understood post-translation modifier, however, several family of ubiquitin-like proteins (UBLs) can modify cellular targets in a parallel but distinct route. Known UBLs include: small ubiquitin-like modifier (SUMO), ubiquitin cross-reactive protein (UCRP, also known as interferon-stimulated gene-15 ISG15), ubiquitin-related modifier-1 (URM1), neuronal-precursor-cell-expressed developmentally downregulated protein-8 (NEDD8, also called Rub1 in S. cerevisiae), human leukocyte antigen F-associated (FAT10), autophagy-8 (ATG8) and -12 (ATG12), Few ubiquitin-like protein (FUB1), MUB (membrane-anchored UBL), ubiquitin fold-modifier-1 (UFM1) and ubiquitin-like protein-5 (UBL5, which is but known as homologous to ubiquitin-1 [Hub1] in S. pombe). Although these proteins share only modest primary sequence identity with ubiquitin, they are closely related three-dimensionally. For example, SUMO shares only 18% sequence identity, but they contain the same structural fold. This fold is called "ubiquitin fold". FAT10 and UCRP contain two. This compact globular beta-grasp fold is found in ubiquitin, UBLs, and proteins that comprise a ubiquitin-like domain, e.g. the S. cerevisiae spindle pole body duplication protein, Dsk2, and NER protein, Rad23, both contain N-terminal ubiquitin domains. These related molecules have novel functions and influence diverse biological processes. There is also cross-regulation between the various conjugation pathways, since some proteins can become modified by more than one UBL, and sometimes even at the same lysine residue.
=== Branding === In 1996, while renovating the first Raising Cane’s location near LSU, Graves uncovered an old mural from a former bakery, "Wolf's Bakery", that inspired the restaurant's logo with its red-brick tones, flowing white script, and a yellow tagline declaring "bread at its best". The name "Raising Cane's" pays tribute to his yellow Labrador, Cane. Locations feature custom murals. These brand elements can be seen in official merchandise released by Raising Cane's. In addition, Raising Cane's sells limited-edition merchandise, like the Graduation Plush Puppy released in 2025. They held a fashion show in 2025 at New York Fashion Week, designed by Joe Ando-Hirsh.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.